• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact

by MM360 Staff | Aug 8, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors

by MM360 Staff | Aug 8, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs

by MM360 Staff | Aug 7, 2025 | Myeloma News

Source: Pharmacy Times articles Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates. Read More

Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?

by MM360 Staff | Aug 7, 2025 | Myeloma News

Source: Pharmacy Times articles CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at 5 years without maintenance. Read More

Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus

by MM360 Staff | Aug 6, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma

by MM360 Staff | Aug 5, 2025 | Myeloma News

Source: Pharmacy Times articles Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission. Read More
« Older Entries
Next Entries »

Recent Content

  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
  • Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
  • Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT